Clinical Trials
12 trialsNCT04449874 2026-06-02
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
Phase 1 Active not recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02942095 2023-04-18
Study of Ixazomib and Erlotinib in Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01302808 2021-01-20
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01284335 2019-01-10
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT00895687 2015-07-13
Study of Erlotinib in Combination With Bortezomib
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00903734 2015-07-13
An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00738751 2015-02-04
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00738335 2012-10-04
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
University of California, San Francisco
Phase 1 Withdrawn
NCT00611468 2011-08-22
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
Accelerated Community Oncology Research Network
Phase 1 Completed